Presentation Information
[1ACCE-07-KL]Advancements in Antibody Manufacturing Processes: Establishment and Application of a Novel CHO Cell Line (CHO-MK)
○Tomohiro Makino1 (1. Daiichi SankyoCo., Ltd (Japan))
Keywords:
Cell line development,Novel CHO cell line,Antibody process development,Cell engineering
The success of antibody therapeutics depends not only on progress in drug discovery research and antibody engineering but also critically on the development of antibody manufacturing processes and the establishment of stable supply systems to produce high-quality products consistently. In particular, innovations that enhance productivity in cell line development, upstream and downstream processes and accelerate manufacturing process development in recent years are key factors that increase competitiveness in the antibody therapeutics market.
To date, Daiichi Sankyo has leveraged cutting-edge technologies in cell line development, culture processes, and purification processes to advance antibody manufacturing process sophistication. Notably, Daiichi Sankyo has recently established a novel CHO cell line, CHO-MK derivative (Masuda et al., J Biosci Bioeng. 2024;137(6):471-479), which differs fundamentally from conventional CHO cells according to our research in the MAB association. This cell line exhibits approximately twofold faster growth rate and extremely high viable cell density in comparison with an existing CHO cell line, suggesting its promising application might provide opportunities to be a game changer in a biologics manufacturing area.
This presentation will introduce the host expression system, cell line development and upstream, and downstream process development using a novel CHO cell line. Furthermore, it will discuss expectations for future technological innovations and the prospective outlook they may bring.
To date, Daiichi Sankyo has leveraged cutting-edge technologies in cell line development, culture processes, and purification processes to advance antibody manufacturing process sophistication. Notably, Daiichi Sankyo has recently established a novel CHO cell line, CHO-MK derivative (Masuda et al., J Biosci Bioeng. 2024;137(6):471-479), which differs fundamentally from conventional CHO cells according to our research in the MAB association. This cell line exhibits approximately twofold faster growth rate and extremely high viable cell density in comparison with an existing CHO cell line, suggesting its promising application might provide opportunities to be a game changer in a biologics manufacturing area.
This presentation will introduce the host expression system, cell line development and upstream, and downstream process development using a novel CHO cell line. Furthermore, it will discuss expectations for future technological innovations and the prospective outlook they may bring.
Comment
To browse or post comments, you must log in.Log in